Prognostic/predictive biomarkers in advanced soft tissue sarcomas (STS): Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin versus doxorubicin--A GEIS study.

Javier Martin Broto,Jorge Martinez-Serra,Rafael Ramos,José Antonio López-Guerrero,Silvia Bagué,Carmen Martínez,Ramiro Alvarez,Xavier Garcia-del-Muro,Ramon De Las Penas,Antonio Gutierrez,Javier Martínez Trufero,Josefina Cruz,A. Poveda,Rosa Maria Alvarez Alvarez,Ricardo Cubedo,Andrés Redondo,J. Maurel,Maria Sala,Jose A. Lopez-Martin,Antonio Lopez-Pousa

Prognostic/predictive biomarkers in advanced soft tissue sarcomas (STS): Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin versus doxorubicin--A GEIS study.

2014

10500 Background: Nucleotide excision and homologous recombination DNA repair pathways are the most recognized antitumor mechanism of action of trabectedin in STS. Additionally, our group has shown...

Keywords:

Trabectedin
Doxorubicin
Biomarker (medicine)
Physical therapy
Soft tissue
Pathology
Medicine
Mechanism of action
predictive biomarker
Translational research
Homologous Recombination DNA Repair

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations